Search

Your search keyword '"Ildikó Seres"' showing total 2 results
Start Over Author "Ildikó Seres" Journal lipids in health and disease
2 results on '"Ildikó Seres"'

1. Serum obestatin level strongly correlates with lipoprotein subfractions in non-diabetic obese patients

Author

Anita Szentpéteri, Hajnalka Lőrincz, Sándor Somodi, Viktória Evelin Varga, György Paragh, Ildikó Seres, and Mariann Harangi

Subjects
Obestatin, Metabolic syndrome, Diabetes, Obesity, Hyperlipidemia, Nutritional diseases. Deficiency diseases, RC620-627
Abstract

Abstract Background Obestatin is a ghrelin-associated peptide, derived from preproghrelin. Although many of its effects are unclear, accumulating evidence supports positive actions on both metabolism and cardiovascular function. To date, level of obestatin and its correlations to the lipid subfractions in non-diabetic obese (NDO) patients have not been investigated. Methods Fifty NDO patients (BMI: 41.96 ± 8.6 kg/m2) and thirty-two normal-weight, age- and gender-matched healthy controls (BMI: 24.16 ± 3.3 kg/m2) were enrolled into our study. Obestatin level was measured by ELISA. Low-density lipoprotein (LDL) and high-density lipoprotein (HDL) subfractions, intermediate density lipoprotein (IDL) and very low-density lipoprotein (VLDL) levels and mean LDL size were detected by nongradient polyacrylamide gel electrophoresis (Lipoprint). Results Serum level of obestatin was significantly lower in NDO patients compared to controls (3.01 ± 0.5 vs. 3.29 ± 0.6 μg/ml, p

Published
2018
Full Text
View/download PDF

2. Impact of selective LDL apheresis on serum chemerin levels in patients with hypercholesterolemia

Author

Péter Fülöp, Viktória Evelin Varga, Noémi Zsíros, Hajnalka Lőrincz, József Balla, György Paragh, Mariann Harangi, and Ildikó Seres

Subjects
Male, medicine.medical_specialty, Clinical chemistry, Endocrinology, Diabetes and Metabolism, Familial hypercholesterolemia, Clinical Biochemistry, Adipokine, 030209 endocrinology & metabolism, 030204 cardiovascular system & hematology, Klinikai orvostudományok, Hyperlipoproteinemia Type II, 03 medical and health sciences, HDL subfractions, 0302 clinical medicine, Endocrinology, Internal medicine, medicine, Humans, Chemerin, LDL subfractions, LDL apheresis, Aged, Biochemistry, medical, biology, business.industry, Research, Biochemistry (medical), Orvostudományok, Middle Aged, Lipid Metabolism, medicine.disease, Lipoproteins, LDL, Apheresis, Blood Component Removal, biology.protein, Intercellular Signaling Peptides and Proteins, Female, lipids (amino acids, peptides, and proteins), Adsorption, Chemokines, business, Lipoprotein, Lipidology
Abstract

Background Selective low-density lipoprotein (LDL) apheresis is commonly used to treat patients with familial hypercholesterolemia (FH). Chemerin is an adipokine with putative roles in the regulation of lipid metabolism. Methods In our pilot study, we measured serum chemerin levels by enzyme-linked immunosorbent assay in six severe heterozygous FH patients before and after their first LDL apheresis treatments using the technique of direct adsorption of lipoproteins (DALI). Results The first treatment sessions decreased serum chemerin levels by an average of 27.26 %. While following one patient, 12 months of regular LDL apheresis resulted in a permanent reduction in his serum chemerin level. Changes in the lipoprotein subfractions measured by gel electrophoresis (Lipoprint) correlated with the reduction of chemerin levels. Furthermore, we eluted and then measured chemerin bound to the DALI column. Conclusion We conclude that LDL apheresis decreases the circulating level of chemerin by binding the protein to the column and thus improves lipoprotein subfraction pattern.

Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results